Centogene NV
NASDAQ:CNTG
Relative Value
There is not enough data to reliably calculate the relative value of CNTG.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
CNTG Competitors Multiples
Centogene NV Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
Centogene NV
NASDAQ:CNTG
|
1.7m USD | 0 | -0 | -1.7 | -1.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.5B USD | 6.6 | 96.2 | 15.8 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.5B USD | 5.5 | 26.4 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.2B USD | 6.2 | 21.3 | 13.3 | 16.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.1B USD | 10.4 | 31.6 | 23.9 | 25 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.9B USD | 5.7 | 18.2 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.2B AUD | 3.1 | 34.6 | 11.4 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
38.5B EUR | 10.9 | 35.1 | 38.1 | 38.9 |